<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00902330</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-11995</org_study_id>
    <secondary_id>HM11995</secondary_id>
    <secondary_id>CDR0000641994</secondary_id>
    <secondary_id>NCI-2011-00234</secondary_id>
    <nct_id>NCT00902330</nct_id>
  </id_info>
  <brief_title>Cranial Stimulation for Chemotherapy Symptoms in Breast Cancer</brief_title>
  <official_title>Cranial Stimulation for Chemotherapy Symptoms in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Cranial microcurrent electrical stimulation (CES) is mild electrical current
      received through electrodes placed on the earlobes. CES may lessen symptoms in women with
      breast cancer receiving chemotherapy. It is not yet known whether CES is more effective than
      sham therapy in reducing symptoms caused by chemotherapy in women with breast cancer.

      PURPOSE: This randomized phase III trial is studying mild electrical stimulation to see how
      well it works compared with sham therapy in reducing symptoms caused by chemotherapy in women
      with stage I, stage II, or stage IIIA breast cancer receiving chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To compare the effects of cranial microcurrent electrical stimulation (CES) vs sham CES
           over time on symptoms of depression, anxiety, fatigue, pain, and sleep disturbances in
           women with stage I-IIIA breast cancer receiving adjuvant chemotherapy.

      Secondary

        -  To explore the relationships among selected markers of inflammation (e.g., tumor
           necrosis factor alpha, interleukin-6, interleukin-1β, and C-reactive protein), symptoms,
           and quality of life.

        -  To examine whether the symptoms of depression, anxiety, fatigue, sleep disturbances, and
           pain form a cluster.

        -  To examine the effects of CES on quality of life.

      OUTLINE: Patients are stratified according to chemotherapy schedule (every 2 weeks for 8
      courses vs every 3 weeks for 6 courses). Patients are randomized to 1 of 2 treatment arms.

        -  Arm I (cranial microcurrent electrical stimulation [CES]): Patients receive a CES unit
           (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of biphasic
           electrical stimulation via ear-lobe electrodes. The CES unit is preset to provide 1 hour
           of 100 μA (sub-sensory level), modified square-wave biphasic stimulation on a 50% duty
           cycle at .05 Hz, and to automatically turn off at the end of 1 hour. Patients use their
           CES unit once daily in weeks 1-18.

        -  Arm II (sham CES): Patients receive a CES unit as in arm I, but the ear-lobe electrodes
           do not pass electrical current. Patients use their CES unit once daily in weeks 1-18.

      Patients complete symptom questionnaires (e.g., the Hospital Anxiety and Depression Scale,
      the Brief Pain Inventory Short-Form, the Brief Fatigue Inventory, and the General Sleep
      Disturbance Scale) weekly in weeks 1-18. Patients also complete a quality-of-life
      questionnaire in weeks 1, 7, and 18.

      Blood samples are collected in weeks 1, 7, and 18 and analyzed for cytokines (e.g., tumor
      necrosis factor alpha, interleukin-6, and interleukin-1β) and C-reactive protein.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of CES as Compared to Sham CES on Symptoms of Depression, Anxiety, Fatigue, Pain and Sleep Disturbances in Women Receiving Adjuvant Chemotherapy for Early-stage Breast Cancer</measure>
    <time_frame>Up to 2 weeks afer completion of study treatment, for up to 8 months</time_frame>
    <description>Using Hospital Anxiety and Depression Scale (HADS) a 14 item scale, 7 relate to anxiety, 7 to depression; each item is scored from 0-3, a person can score 0 to 21 for either anxiety or depression (0 is best and 21 is worst), Brief Pain Inventory (BPI) short-form measures the intensity and interference of pain in the patient's life; 12 questions with 0 (does not interfere) to 10 (completely interferes); mean will be used as the measure of pain; Brief Fatigue Inventory (BFI) assess the severity and impact of cancer-related fatigue. Has 9 questions with 0 (does not interfere) to 10 (completely interferes), the total mean score is the mean of the 9 questions; severe fatigue can be defined as a score of 7 or higher, General Sleep Disturbance Scale (GSDS) 21 items to evaluate sleep issues (0=never to 7=every day); the 21 items are summed to produce a total score of 9=no sleep disturbance to 137=extreme sleep disturbance . Used standard questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Examine Whether the Symptoms of Depression, Anxiety, Fatigue, Sleep Disturbances and Pain Form a Cluster.</measure>
    <time_frame>up to 2 weeks after completion of study treatment, for up to 8 months</time_frame>
    <description>Examine correlations between the symptoms at baseline to determine a general pattern of association. Factor analysis (a statistical method used to describe variability among observed, correlated variables in terms of a potentially lower number of unobserved variables called factors) was performed to examine how these 5 symptoms cluster. A principal component factor analysis was performed on the correlation matrix for the symptom scores of anxiety, depression, pain, fatigue and sleep disturbance at up to two weeks after completion of study treatment, up to 8 months). For each analysis two factors were retained that explained 74% of the variability for the baseline symptom scores, 79% of the variability of the symptom scores at the midpoint and 78% of the variability in symptom scores at study completion. A varimax rotation was utilized and the factor loadings from the varimax rotation were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Means and Standard Deviations of Biomarkers Log(CRP pg/ml), Log(IL-1b pg/ml), Log(IL-6 pg/ml) and Log(TNF-a pg/ml).</measure>
    <time_frame>Baseline</time_frame>
    <description>Simple correlations will be computed at Midpoint Chemotherapy for the log transformed biomarker values; IL1-β, IL-6, TNF-α, CRP. These are the biomarkers of inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationships Among Biomarkers Log(CRP pg/ml), Log(IL-1b pg/ml), Log(IL-6 pg/ml) and Log(TNF-a pg/ml).</measure>
    <time_frame>Baseline</time_frame>
    <description>Simple correlations will be computed at Baseline for the log transformed biomarker values; IL1-β, IL-6, TNF-α, CRP. These are the biomarkers of inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationships Among Anxiety, Depression, Fatigue, Pain and Sleep Scores - Means at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using Hospital Anxiety and Depression Scale (HADS) a fourteen item scale, 7 relate to anxiety and 7 to depression; each item is scored from 0-3, this means a person can score 0 to 21 for either anxiety or depression (0 is best and 21 is worst), Brief Pain Inventory (BPI) short-form measures the intensity of pain and interference of pain in the patient's life; 12 questions with 0 (does not interfere) to 10 (completely interferes); mean will be used as the measure of pain; Brief Fatigue Inventory (BFI) assess the severity and impact of cancer-related fatigue. it has 9 questions with 0 (does not interfere) to 10 (completely interferes); severe fatigue can be defined as a score of 7 or higher, General Sleep Disturbance Scale (GSDS) 21 items to evaluate sleep issues (0=never to 7=every day); the 21 items are summed to produce a total score of 9=no sleep disturbance to 137=extreme sleep disturbance . Used standard questionnaire scoring system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationships Among Symptom Scores - Correlations at Baseline Chemotherapy</measure>
    <time_frame>Baseline</time_frame>
    <description>Simple correlations will be computed at Baseline Chemotherapy for symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationships Among Quality of Life Scores - Means at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using the Functional Assessment of Cancer Therapy for Patients with Breast Cancer (FACT-B). A 44-item self-report instrument designed to measure multidimensional quality of life in patient with breast cancer. 0=not at all to 4=very much. Utilized standard questionnaire scoring system. The items are summed to produce a total score 0=not at all to 176=very much. The FACT-B BCA has 10 questions that range from 0 (not at all) to 4 (very much); thus the FACT-B BCA ranges from 0 to 40. Both the FACT-B and FACT-BCA are scored so that high scores indicate higher levels of quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationships Among Quality of Life Scores - Correlations at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Simple correlations will be computed at Baseline for quality of life scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and Standard Deviation of Biomarkers Log(CRP pg/ml), Log(IL-1b pg/ml), Log(IL-6 pg/ml) and Log(TNF-a pg/ml).</measure>
    <time_frame>Midpoint Chemotherapy, up to 4 months</time_frame>
    <description>Simple correlations will be computed at Midpoint Chemotherapy for the log transformed biomarker values; IL1-β, IL-6, TNF-α, CRP. These are the biomarkers of inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationships Among Biomarkers Log (CRP), Log (IL-1B), Log (IL6), and Log (TNF-a) - Correlations at Midpoint Chemotherapy</measure>
    <time_frame>Midpoint Chemotherapy, up to 4 months</time_frame>
    <description>Simple correlations will be computed at Midpoint Chemotherapy for the log transformed biomarker values; IL1-β, IL-6, TNF-α, CRP. These are the biomarkers of inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationships Among Anxiety, Depression, Fatigue, Pain and Sleep Scores - Means at Midpoint Chemotherapy</measure>
    <time_frame>Midpoint Chemotherapy, up to 4 months</time_frame>
    <description>Measured using Hospital Anxiety and Depression Scale (HADS) a fourteen item scale, 7 relate to anxiety and 7 to depression; each item is scored from 0-3, this means a person can score 0 to 21 for either anxiety or depression (0 is best and 21 is worst), Brief Pain Inventory (BPI) short-form measures the intensity of pain and interference of pain in the patient's life; 12 questions with 0 (does not interfere) to 10 (completely interferes); mean will be used as the measure of pain; Brief Fatigue Inventory (BFI) assess the severity and impact of cancer-related fatigue. it has 9 questions with 0 (does not interfere) to 10 (completely interferes); severe fatigue can be defined as a score of 7 or higher, General Sleep Disturbance Scale (GSDS) 21 items to evaluate sleep issues (0=never to 7=every day); the 21 items are summed to produce a total score of 9=no sleep disturbance to 137=extreme sleep disturbance . Used standard questionnaire scoring system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationships Among Symptom Scores - Correlations at Midpoint Chemotherapy</measure>
    <time_frame>Midpoint Chemotherapy, up to 4 months</time_frame>
    <description>Simple correlations will be computed at Midpoint Chemotherapy for symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationships Among Quality of Life Scores - Means at Midpoint Chemotherapy</measure>
    <time_frame>Midpoint Chemotherapy, up to 4 months</time_frame>
    <description>Measured using the Functional Assessment of Cancer Therapy for Patients with Breast Cancer (FACT-B). A 44-item self-report instrument designed to measure multidimensional quality of life in patient with breast cancer. 0=not at all to 4=very much. Utilized standard questionnaire scoring system. The items are summed to produce a total score 0=not at all to 176=very much. The FACT-B BCA has 10 questions that range from 0 (not at all) to 4 (very much); thus the FACT-B BCA ranges from 0 to 40. Both the FACT-B and FACT-BCA are scored so that high scores indicate higher levels of quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationships Among Quality of Life Scores - Correlations at Midpoint Chemotherapy</measure>
    <time_frame>Midpoint Chemotherapy, up to 4 months</time_frame>
    <description>Simple correlations will be computed at Midpoint Chemotherapy for quality of life scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and Standard Deviation of Biomarkers Log(CRP pg/ml), Log(IL-1b pg/ml), Log(IL-6 pg/ml) and Log(TNF-a pg/ml).</measure>
    <time_frame>Up to 2 weeks after completion of study treatment, for up to 8 months</time_frame>
    <description>Simple correlations will be computed after completion of study treatment for the log transformed biomarker values; IL1-β, IL-6, TNF-α, CRP. These are the biomarkers of inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationships Among Biomarkers Log (CRP), Log (IL-1B), Log (IL6), and Log (TNF-a) - Correlations at End of Treatment</measure>
    <time_frame>Up to 2 weeks afer completion of study treatment, for up to 8 months</time_frame>
    <description>Simple correlations will be computed at Chemotherapy End of Treatment for the log transformed biomarker values; IL1-β, IL-6, TNF-α, CRP. These are the biomarkers of inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationships Among Anxiety, Depression, Fatigue, Pain and Sleep Scores - Means at End of Chemotherapy</measure>
    <time_frame>Up to 2 weeks afer completion of study treatment, for up to 8 months</time_frame>
    <description>Measured using Hospital Anxiety and Depression Scale (HADS) a fourteen item scale, 7 relate to anxiety and 7 to depression; each item is scored from 0-3, this means a person can score 0 to 21 for either anxiety or depression (0 is best and 21 is worst), Brief Pain Inventory (BPI) short-form measures the intensity of pain and interference of pain in the patient's life; 12 questions with 0 (does not interfere) to 10 (completely interferes); mean will be used as the measure of pain; Brief Fatigue Inventory (BFI) assess the severity and impact of cancer-related fatigue. it has 9 questions with 0 (does not interfere) to 10 (completely interferes); severe fatigue can be defined as a score of 7 or higher, General Sleep Disturbance Scale (GSDS) 21 items to evaluate sleep issues (0=never to 7=every day); the 21 items are summed to produce a total score of 9=no sleep disturbance to 137=extreme sleep disturbance . Used standard questionnaire scoring system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationships Among Symptom Scores - Correlations at End of Chemotherapy</measure>
    <time_frame>Up to 2 weeks afer completion of study treatment, for up to 8 months</time_frame>
    <description>Simple correlations will be computed at end of Chemotherapy for symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of Treatment on Quality of Life - Means at End of Treatment</measure>
    <time_frame>up to 2 weeks after completion of study treatment, for up to 8 months</time_frame>
    <description>Measured using the Functional Assessment of Cancer Therapy for Patients with Breast Cancer (FACT-B). A 44-item self-report instrument designed to measure multidimensional quality of life in patient with breast cancer. 0=not at all to 4=very much. Utilized standard questionnaire scoring system. The items are summed to produce a total score 0=not al all to 176=very much. The FACT-B BCA has 10 questions that range from 0 (not at all) to 4 (very much); thus the FACT-B BCA ranges from 0 to 40. Both the FACT-B and FACT-BCA are scored so that high scores indicate higher levels of quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationships Among Quality of Life Scores - Correlations at End of Chemotherapy</measure>
    <time_frame>Up to 2 weeks afer completion of study treatment, for up to 8 months</time_frame>
    <description>Simple correlations will be computed at End of Chemotherapy for quality of life scores.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Anxiety Disorder</condition>
  <condition>Breast Cancer</condition>
  <condition>Depression</condition>
  <condition>Fatigue</condition>
  <condition>Pain</condition>
  <condition>Sleep Disorders</condition>
  <arm_group>
    <arm_group_label>Arm I (cranial microcurrent electrical stimulation [CES])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of biphasic electrical stimulation via ear-lobe electrodes. The CES unit is preset to provide 1 hour of 100 μA (sub-sensory level), modified square-wave biphasic stimulation on a 50% duty cycle at .05 Hz, and to automatically turn off at the end of 1 hour. Patients use their CES unit once daily in weeks 1-18.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (sham CES)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients receive a CES unit as in arm I, but the ear-lobe electrodes do not pass electrical current. Patients use their CES unit once daily in weeks 1-18.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>energy-based therapy</intervention_name>
    <description>Given once a day for 18 weeks</description>
    <arm_group_label>Arm I (cranial microcurrent electrical stimulation [CES])</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sham intervention</intervention_name>
    <description>Given once a day for 18 weeks</description>
    <arm_group_label>Arm II (sham CES)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of stage I-IIIA breast cancer

          -  Scheduled to receive adjuvant chemotherapy

          -  Hormone receptor status not specified

        PATIENT CHARACTERISTICS:

          -  Pre, peri, or post-menopausal

          -  ECOG performance status 0-1

          -  No dementia

          -  No active psychosis

          -  No history of seizure disorder

          -  No implanted electrical device

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior chemotherapy

          -  No initiation of a medication regimen for depression or other psychiatric condition
             within the past 30 days
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah McGuire, PhD,RN,FAAN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massey Cancer Center</affiliation>
  </overall_official>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2009</study_first_submitted>
  <study_first_submitted_qc>May 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2009</study_first_posted>
  <results_first_submitted>May 15, 2014</results_first_submitted>
  <results_first_submitted_qc>March 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 2, 2015</results_first_posted>
  <last_update_submitted>November 19, 2015</last_update_submitted>
  <last_update_submitted_qc>November 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>anxiety disorder</keyword>
  <keyword>fatigue</keyword>
  <keyword>pain</keyword>
  <keyword>sleep disorders</keyword>
  <keyword>stage IA breast cancer</keyword>
  <keyword>stage IB breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Women with stage I to IIIA breast cancer scheduled to receive chemotherapy with a performance score &lt;2 recruited from five Cancer Centers across Virginia. Previous chemotherapy, dementia or active psychosis, seizure disorder, implanted electrical device, or taking medication psychiatric condition with 30 days prior to enrollment were excluded.</recruitment_details>
      <pre_assignment_details>Following completion of informed consent study participants were stratified by initial chemotherapy regimen (dose dense versus non-dose dense) and then randomly assigned to one of two groups: actual or sham CES.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Cranial Microcurrent Electrical Stimulation [CES])</title>
          <description>Patients receive a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of biphasic electrical stimulation via ear-lobe electrodes. The CES unit is preset to provide 1 hour of 100 μA (sub-sensory level), modified square-wave biphasic stimulation on a 50% duty cycle at .05 Hz, and to automatically turn off at the end of 1 hour. Patients use their CES unit once daily in weeks 1-18.
energy-based therapy: Given once a day for 18 weeks</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Sham CES)</title>
          <description>Patients receive a CES unit as in arm I, but the ear-lobe electrodes do not pass electrical current. Patients use their CES unit once daily in weeks 1-18.
sham intervention: Given once a day for 18 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Too overwhelmed by treatment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No post baseline data</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients who completed trial</population>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Cranial Microcurrent Electrical Stimulation [CES])</title>
          <description>Patients receive a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of biphasic electrical stimulation via ear-lobe electrodes. The CES unit is preset to provide 1 hour of 100 μA (sub-sensory level), modified square-wave biphasic stimulation on a 50% duty cycle at .05 Hz, and to automatically turn off at the end of 1 hour. Patients use their CES unit once daily in weeks 1-18.
energy-based therapy: Given once a day for 18 weeks</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Sham CES)</title>
          <description>Patients receive a CES unit as in arm I, but the ear-lobe electrodes do not pass electrical current. Patients use their CES unit once daily in weeks 1-18.
sham intervention: Given once a day for 18 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="77"/>
            <count group_id="B2" value="75"/>
            <count group_id="B3" value="152"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.03" spread="11.06"/>
                    <measurement group_id="B2" value="51.41" spread="8.55"/>
                    <measurement group_id="B3" value="51.22" spread="9.805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage of Disease</title>
          <description>Staged with TNM classifications. The TNM system is based on the size and/or extent (reach) of the primary tumor (T), the amount of spread to nearby lymph nodes (N), and the presence of metastasis (M) or secondary tumors formed by the spread of cancer cells to other parts of the body.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Phase I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effects of CES as Compared to Sham CES on Symptoms of Depression, Anxiety, Fatigue, Pain and Sleep Disturbances in Women Receiving Adjuvant Chemotherapy for Early-stage Breast Cancer</title>
        <description>Using Hospital Anxiety and Depression Scale (HADS) a 14 item scale, 7 relate to anxiety, 7 to depression; each item is scored from 0-3, a person can score 0 to 21 for either anxiety or depression (0 is best and 21 is worst), Brief Pain Inventory (BPI) short-form measures the intensity and interference of pain in the patient's life; 12 questions with 0 (does not interfere) to 10 (completely interferes); mean will be used as the measure of pain; Brief Fatigue Inventory (BFI) assess the severity and impact of cancer-related fatigue. Has 9 questions with 0 (does not interfere) to 10 (completely interferes), the total mean score is the mean of the 9 questions; severe fatigue can be defined as a score of 7 or higher, General Sleep Disturbance Scale (GSDS) 21 items to evaluate sleep issues (0=never to 7=every day); the 21 items are summed to produce a total score of 9=no sleep disturbance to 137=extreme sleep disturbance . Used standard questionnaire</description>
        <time_frame>Up to 2 weeks afer completion of study treatment, for up to 8 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Cranial Microcurrent Electrical Stimulation [CES])</title>
            <description>Patients receive a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of biphasic electrical stimulation via ear-lobe electrodes. The CES unit is preset to provide 1 hour of 100 μA (sub-sensory level), modified square-wave biphasic stimulation on a 50% duty cycle at .05 Hz, and to automatically turn off at the end of 1 hour. Patients use their CES unit once daily in weeks 1-18.
energy-based therapy: Given once a day for 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Sham CES)</title>
            <description>Patients receive a CES unit as in arm I, but the ear-lobe electrodes do not pass electrical current. Patients use their CES unit once daily in weeks 1-18.
sham intervention: Given once a day for 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of CES as Compared to Sham CES on Symptoms of Depression, Anxiety, Fatigue, Pain and Sleep Disturbances in Women Receiving Adjuvant Chemotherapy for Early-stage Breast Cancer</title>
          <description>Using Hospital Anxiety and Depression Scale (HADS) a 14 item scale, 7 relate to anxiety, 7 to depression; each item is scored from 0-3, a person can score 0 to 21 for either anxiety or depression (0 is best and 21 is worst), Brief Pain Inventory (BPI) short-form measures the intensity and interference of pain in the patient's life; 12 questions with 0 (does not interfere) to 10 (completely interferes); mean will be used as the measure of pain; Brief Fatigue Inventory (BFI) assess the severity and impact of cancer-related fatigue. Has 9 questions with 0 (does not interfere) to 10 (completely interferes), the total mean score is the mean of the 9 questions; severe fatigue can be defined as a score of 7 or higher, General Sleep Disturbance Scale (GSDS) 21 items to evaluate sleep issues (0=never to 7=every day); the 21 items are summed to produce a total score of 9=no sleep disturbance to 137=extreme sleep disturbance . Used standard questionnaire</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.040" spread="0.419"/>
                    <measurement group_id="O2" value="4.529" spread="0.431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.520" spread="0.398"/>
                    <measurement group_id="O2" value="4.565" spread="0.407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.349" spread="0.294"/>
                    <measurement group_id="O2" value="3.191" spread="0.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.174" spread="0.197"/>
                    <measurement group_id="O2" value="1.272" spread="0.202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.235" spread="2.376"/>
                    <measurement group_id="O2" value="40.474" spread="2.443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Examine Whether the Symptoms of Depression, Anxiety, Fatigue, Sleep Disturbances and Pain Form a Cluster.</title>
        <description>Examine correlations between the symptoms at baseline to determine a general pattern of association. Factor analysis (a statistical method used to describe variability among observed, correlated variables in terms of a potentially lower number of unobserved variables called factors) was performed to examine how these 5 symptoms cluster. A principal component factor analysis was performed on the correlation matrix for the symptom scores of anxiety, depression, pain, fatigue and sleep disturbance at up to two weeks after completion of study treatment, up to 8 months). For each analysis two factors were retained that explained 74% of the variability for the baseline symptom scores, 79% of the variability of the symptom scores at the midpoint and 78% of the variability in symptom scores at study completion. A varimax rotation was utilized and the factor loadings from the varimax rotation were reported.</description>
        <time_frame>up to 2 weeks after completion of study treatment, for up to 8 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients Analyzed</title>
            <description>All patients</description>
          </group>
        </group_list>
        <measure>
          <title>To Examine Whether the Symptoms of Depression, Anxiety, Fatigue, Sleep Disturbances and Pain Form a Cluster.</title>
          <description>Examine correlations between the symptoms at baseline to determine a general pattern of association. Factor analysis (a statistical method used to describe variability among observed, correlated variables in terms of a potentially lower number of unobserved variables called factors) was performed to examine how these 5 symptoms cluster. A principal component factor analysis was performed on the correlation matrix for the symptom scores of anxiety, depression, pain, fatigue and sleep disturbance at up to two weeks after completion of study treatment, up to 8 months). For each analysis two factors were retained that explained 74% of the variability for the baseline symptom scores, 79% of the variability of the symptom scores at the midpoint and 78% of the variability in symptom scores at study completion. A varimax rotation was utilized and the factor loadings from the varimax rotation were reported.</description>
          <units>Rotated factor loading multiplied by 100</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anxiety Factor 1 Loading-Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxeity Factor 2 Loading-Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety Factor 1 Loading-Midpoint Chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety Factor 2 Loading-Midpoint Chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety Factor 1 Loading-Post Chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety Factor 2 Loading-Post Chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression Factor 1 Loading-Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression Factor 2 Loading-Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression Factor 1 Loading-Midpoint Chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression Factor 2 Loading-Midpoint Chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression Factor 1 Loading-Post Chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression Factor 2 Loading-Post Chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue Factor 1 Loading-Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue Factor 2 Loading-Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue Factor 1 Loading-Midpoint Chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue Factor 2 Loading-Midpoint Chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue Factor 1 Loading-Post Chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue Factor 2 Loading-Post Chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Factor 1 Loading-Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Factor 2 Loading-Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Factor 1 Loading-Midpoint Chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Factor 2 Loading-Midpoint Chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Factor 1 Loading-Post Chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Factor 2 Loading-Post Chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Factor 1 Loading-Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Factor 2 Loading-Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Factor 1 Loading-Midpoint Chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Factor 2 Loading-Midpoint Chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Factor 1 Loading-Post Chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Factor 2 Loading-Post Chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Means and Standard Deviations of Biomarkers Log(CRP pg/ml), Log(IL-1b pg/ml), Log(IL-6 pg/ml) and Log(TNF-a pg/ml).</title>
        <description>Simple correlations will be computed at Midpoint Chemotherapy for the log transformed biomarker values; IL1-β, IL-6, TNF-α, CRP. These are the biomarkers of inflammation.</description>
        <time_frame>Baseline</time_frame>
        <population>Per protocol, for all subjects with available data. No imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Cranial Microcurrent Electrical Stimulation (CES)</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Sham CES</description>
          </group>
        </group_list>
        <measure>
          <title>Means and Standard Deviations of Biomarkers Log(CRP pg/ml), Log(IL-1b pg/ml), Log(IL-6 pg/ml) and Log(TNF-a pg/ml).</title>
          <description>Simple correlations will be computed at Midpoint Chemotherapy for the log transformed biomarker values; IL1-β, IL-6, TNF-α, CRP. These are the biomarkers of inflammation.</description>
          <population>Per protocol, for all subjects with available data. No imputation was utilized.</population>
          <units>Log(pg/ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Log(CRP pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.64" spread="1.67"/>
                    <measurement group_id="O2" value="28.92" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Log(IL-1b pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.88" spread="69.85"/>
                    <measurement group_id="O2" value="32.60" spread="259.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Log(IL-6 pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="2.65"/>
                    <measurement group_id="O2" value="0.09" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Log(TNF-a pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="3.49"/>
                    <measurement group_id="O2" value="-0.19" spread="3.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Spearman correlation coefficients were computed for the biomarkers. P-Values shown are not adjusted for multiple comparisons. The a priori threshold for statistical significance was P less than 0.05. This information applies to all rows listed in the table.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationships Among Biomarkers Log(CRP pg/ml), Log(IL-1b pg/ml), Log(IL-6 pg/ml) and Log(TNF-a pg/ml).</title>
        <description>Simple correlations will be computed at Baseline for the log transformed biomarker values; IL1-β, IL-6, TNF-α, CRP. These are the biomarkers of inflammation.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients Analyzed</title>
            <description>All patients</description>
          </group>
        </group_list>
        <measure>
          <title>Relationships Among Biomarkers Log(CRP pg/ml), Log(IL-1b pg/ml), Log(IL-6 pg/ml) and Log(TNF-a pg/ml).</title>
          <description>Simple correlations will be computed at Baseline for the log transformed biomarker values; IL1-β, IL-6, TNF-α, CRP. These are the biomarkers of inflammation.</description>
          <units>correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Correlation between Log (CRP)-Log (IL-1B)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Log (CRP)-Log IL6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Log (CRP)-Log (TNF-a)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Log (IL-1B)-Log (IL6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Log (IL-1B)-Log (TNF-a)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Log (IL6)-Log (TNF-a)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationships Among Anxiety, Depression, Fatigue, Pain and Sleep Scores - Means at Baseline</title>
        <description>Measured using Hospital Anxiety and Depression Scale (HADS) a fourteen item scale, 7 relate to anxiety and 7 to depression; each item is scored from 0-3, this means a person can score 0 to 21 for either anxiety or depression (0 is best and 21 is worst), Brief Pain Inventory (BPI) short-form measures the intensity of pain and interference of pain in the patient's life; 12 questions with 0 (does not interfere) to 10 (completely interferes); mean will be used as the measure of pain; Brief Fatigue Inventory (BFI) assess the severity and impact of cancer-related fatigue. it has 9 questions with 0 (does not interfere) to 10 (completely interferes); severe fatigue can be defined as a score of 7 or higher, General Sleep Disturbance Scale (GSDS) 21 items to evaluate sleep issues (0=never to 7=every day); the 21 items are summed to produce a total score of 9=no sleep disturbance to 137=extreme sleep disturbance . Used standard questionnaire scoring system.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Cranial Microcurrent Electrical Stimulation (CES)</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Sham CES</description>
          </group>
        </group_list>
        <measure>
          <title>Relationships Among Anxiety, Depression, Fatigue, Pain and Sleep Scores - Means at Baseline</title>
          <description>Measured using Hospital Anxiety and Depression Scale (HADS) a fourteen item scale, 7 relate to anxiety and 7 to depression; each item is scored from 0-3, this means a person can score 0 to 21 for either anxiety or depression (0 is best and 21 is worst), Brief Pain Inventory (BPI) short-form measures the intensity of pain and interference of pain in the patient's life; 12 questions with 0 (does not interfere) to 10 (completely interferes); mean will be used as the measure of pain; Brief Fatigue Inventory (BFI) assess the severity and impact of cancer-related fatigue. it has 9 questions with 0 (does not interfere) to 10 (completely interferes); severe fatigue can be defined as a score of 7 or higher, General Sleep Disturbance Scale (GSDS) 21 items to evaluate sleep issues (0=never to 7=every day); the 21 items are summed to produce a total score of 9=no sleep disturbance to 137=extreme sleep disturbance . Used standard questionnaire scoring system.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.09" spread="4.09"/>
                    <measurement group_id="O2" value="7.59" spread="4.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.03" spread="2.48"/>
                    <measurement group_id="O2" value="3.06" spread="2.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="2.71"/>
                    <measurement group_id="O2" value="2.63" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" spread="2.05"/>
                    <measurement group_id="O2" value="1.45" spread="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.70" spread="24.83"/>
                    <measurement group_id="O2" value="40.30" spread="23.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationships Among Symptom Scores - Correlations at Baseline Chemotherapy</title>
        <description>Simple correlations will be computed at Baseline Chemotherapy for symptoms.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients Analyzed</title>
            <description>All patients</description>
          </group>
        </group_list>
        <measure>
          <title>Relationships Among Symptom Scores - Correlations at Baseline Chemotherapy</title>
          <description>Simple correlations will be computed at Baseline Chemotherapy for symptoms.</description>
          <units>correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Correlation between Anxiety-Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Anxiety-Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Anxiety-Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Anxiety-Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Depression-Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Depression-Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Depression-Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Fatigue-Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Fatigue-Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Pain-Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationships Among Quality of Life Scores - Means at Baseline</title>
        <description>Measured using the Functional Assessment of Cancer Therapy for Patients with Breast Cancer (FACT-B). A 44-item self-report instrument designed to measure multidimensional quality of life in patient with breast cancer. 0=not at all to 4=very much. Utilized standard questionnaire scoring system. The items are summed to produce a total score 0=not at all to 176=very much. The FACT-B BCA has 10 questions that range from 0 (not at all) to 4 (very much); thus the FACT-B BCA ranges from 0 to 40. Both the FACT-B and FACT-BCA are scored so that high scores indicate higher levels of quality of life.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Cranial Microcurrent Electrical Stimulation (CES)</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Sham CES</description>
          </group>
        </group_list>
        <measure>
          <title>Relationships Among Quality of Life Scores - Means at Baseline</title>
          <description>Measured using the Functional Assessment of Cancer Therapy for Patients with Breast Cancer (FACT-B). A 44-item self-report instrument designed to measure multidimensional quality of life in patient with breast cancer. 0=not at all to 4=very much. Utilized standard questionnaire scoring system. The items are summed to produce a total score 0=not at all to 176=very much. The FACT-B BCA has 10 questions that range from 0 (not at all) to 4 (very much); thus the FACT-B BCA ranges from 0 to 40. Both the FACT-B and FACT-BCA are scored so that high scores indicate higher levels of quality of life.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FACT-B Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.44" spread="17.65"/>
                    <measurement group_id="O2" value="111.83" spread="17.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACT-B BCA Specific</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.42" spread="5.05"/>
                    <measurement group_id="O2" value="26.05" spread="6.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationships Among Quality of Life Scores - Correlations at Baseline</title>
        <description>Simple correlations will be computed at Baseline for quality of life scores.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients Analyzed</title>
            <description>All patients</description>
          </group>
        </group_list>
        <measure>
          <title>Relationships Among Quality of Life Scores - Correlations at Baseline</title>
          <description>Simple correlations will be computed at Baseline for quality of life scores.</description>
          <units>correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.744"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean and Standard Deviation of Biomarkers Log(CRP pg/ml), Log(IL-1b pg/ml), Log(IL-6 pg/ml) and Log(TNF-a pg/ml).</title>
        <description>Simple correlations will be computed at Midpoint Chemotherapy for the log transformed biomarker values; IL1-β, IL-6, TNF-α, CRP. These are the biomarkers of inflammation.</description>
        <time_frame>Midpoint Chemotherapy, up to 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Cranial Microcurrent Electrical Stimulation (CES)</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Sham CES</description>
          </group>
        </group_list>
        <measure>
          <title>Mean and Standard Deviation of Biomarkers Log(CRP pg/ml), Log(IL-1b pg/ml), Log(IL-6 pg/ml) and Log(TNF-a pg/ml).</title>
          <description>Simple correlations will be computed at Midpoint Chemotherapy for the log transformed biomarker values; IL1-β, IL-6, TNF-α, CRP. These are the biomarkers of inflammation.</description>
          <units>Log (pg/ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Log (CRP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.62" spread="1.69"/>
                    <measurement group_id="O2" value="29.09" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Log (IL-1B)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.52" spread="52.59"/>
                    <measurement group_id="O2" value="24.68" spread="171.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Log (IL6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="2.91"/>
                    <measurement group_id="O2" value="0.55" spread="2.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Log (TNF-a)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.89" spread="3.52"/>
                    <measurement group_id="O2" value="-0.15" spread="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationships Among Biomarkers Log (CRP), Log (IL-1B), Log (IL6), and Log (TNF-a) - Correlations at Midpoint Chemotherapy</title>
        <description>Simple correlations will be computed at Midpoint Chemotherapy for the log transformed biomarker values; IL1-β, IL-6, TNF-α, CRP. These are the biomarkers of inflammation.</description>
        <time_frame>Midpoint Chemotherapy, up to 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients Analyzed</title>
            <description>All patients</description>
          </group>
        </group_list>
        <measure>
          <title>Relationships Among Biomarkers Log (CRP), Log (IL-1B), Log (IL6), and Log (TNF-a) - Correlations at Midpoint Chemotherapy</title>
          <description>Simple correlations will be computed at Midpoint Chemotherapy for the log transformed biomarker values; IL1-β, IL-6, TNF-α, CRP. These are the biomarkers of inflammation.</description>
          <units>correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Correlation between Log (CRP)-Log (IL-1B)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Log (CRP)-Log IL6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Log (CRP)-Log (TNF-a)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Log (IL-1B)-Log (IL6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Log (IL-1B)-Log (TNF-a)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Log (IL6)-Log (TNF-a)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationships Among Anxiety, Depression, Fatigue, Pain and Sleep Scores - Means at Midpoint Chemotherapy</title>
        <description>Measured using Hospital Anxiety and Depression Scale (HADS) a fourteen item scale, 7 relate to anxiety and 7 to depression; each item is scored from 0-3, this means a person can score 0 to 21 for either anxiety or depression (0 is best and 21 is worst), Brief Pain Inventory (BPI) short-form measures the intensity of pain and interference of pain in the patient's life; 12 questions with 0 (does not interfere) to 10 (completely interferes); mean will be used as the measure of pain; Brief Fatigue Inventory (BFI) assess the severity and impact of cancer-related fatigue. it has 9 questions with 0 (does not interfere) to 10 (completely interferes); severe fatigue can be defined as a score of 7 or higher, General Sleep Disturbance Scale (GSDS) 21 items to evaluate sleep issues (0=never to 7=every day); the 21 items are summed to produce a total score of 9=no sleep disturbance to 137=extreme sleep disturbance . Used standard questionnaire scoring system.</description>
        <time_frame>Midpoint Chemotherapy, up to 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Cranial Microcurrent Electrical Stimulation (CES)</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Sham CES</description>
          </group>
        </group_list>
        <measure>
          <title>Relationships Among Anxiety, Depression, Fatigue, Pain and Sleep Scores - Means at Midpoint Chemotherapy</title>
          <description>Measured using Hospital Anxiety and Depression Scale (HADS) a fourteen item scale, 7 relate to anxiety and 7 to depression; each item is scored from 0-3, this means a person can score 0 to 21 for either anxiety or depression (0 is best and 21 is worst), Brief Pain Inventory (BPI) short-form measures the intensity of pain and interference of pain in the patient's life; 12 questions with 0 (does not interfere) to 10 (completely interferes); mean will be used as the measure of pain; Brief Fatigue Inventory (BFI) assess the severity and impact of cancer-related fatigue. it has 9 questions with 0 (does not interfere) to 10 (completely interferes); severe fatigue can be defined as a score of 7 or higher, General Sleep Disturbance Scale (GSDS) 21 items to evaluate sleep issues (0=never to 7=every day); the 21 items are summed to produce a total score of 9=no sleep disturbance to 137=extreme sleep disturbance . Used standard questionnaire scoring system.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.40" spread="3.19"/>
                    <measurement group_id="O2" value="4.98" spread="3.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.24" spread="3.22"/>
                    <measurement group_id="O2" value="4.02" spread="3.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.15" spread="2.21"/>
                    <measurement group_id="O2" value="3.14" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="1.44"/>
                    <measurement group_id="O2" value="1.09" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.70" spread="18.28"/>
                    <measurement group_id="O2" value="42.44" spread="21.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationships Among Symptom Scores - Correlations at Midpoint Chemotherapy</title>
        <description>Simple correlations will be computed at Midpoint Chemotherapy for symptoms.</description>
        <time_frame>Midpoint Chemotherapy, up to 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients Analyzed</title>
            <description>All patients</description>
          </group>
        </group_list>
        <measure>
          <title>Relationships Among Symptom Scores - Correlations at Midpoint Chemotherapy</title>
          <description>Simple correlations will be computed at Midpoint Chemotherapy for symptoms.</description>
          <units>correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Correlation between Anxiety-Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.723"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Anxiety-Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Anxiety-Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Anxiety-Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Depression-Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Depression-Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Depression-Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Fatigue-Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Fatigue-Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Pain-Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationships Among Quality of Life Scores - Means at Midpoint Chemotherapy</title>
        <description>Measured using the Functional Assessment of Cancer Therapy for Patients with Breast Cancer (FACT-B). A 44-item self-report instrument designed to measure multidimensional quality of life in patient with breast cancer. 0=not at all to 4=very much. Utilized standard questionnaire scoring system. The items are summed to produce a total score 0=not at all to 176=very much. The FACT-B BCA has 10 questions that range from 0 (not at all) to 4 (very much); thus the FACT-B BCA ranges from 0 to 40. Both the FACT-B and FACT-BCA are scored so that high scores indicate higher levels of quality of life.</description>
        <time_frame>Midpoint Chemotherapy, up to 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Cranial Microcurrent Electrical Stimulation (CES)</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Sham CES</description>
          </group>
        </group_list>
        <measure>
          <title>Relationships Among Quality of Life Scores - Means at Midpoint Chemotherapy</title>
          <description>Measured using the Functional Assessment of Cancer Therapy for Patients with Breast Cancer (FACT-B). A 44-item self-report instrument designed to measure multidimensional quality of life in patient with breast cancer. 0=not at all to 4=very much. Utilized standard questionnaire scoring system. The items are summed to produce a total score 0=not at all to 176=very much. The FACT-B BCA has 10 questions that range from 0 (not at all) to 4 (very much); thus the FACT-B BCA ranges from 0 to 40. Both the FACT-B and FACT-BCA are scored so that high scores indicate higher levels of quality of life.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FACT-B Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.57" spread="18.35"/>
                    <measurement group_id="O2" value="108.45" spread="22.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACT-B BCA Specific</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.96" spread="5.47"/>
                    <measurement group_id="O2" value="25.96" spread="5.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationships Among Quality of Life Scores - Correlations at Midpoint Chemotherapy</title>
        <description>Simple correlations will be computed at Midpoint Chemotherapy for quality of life scores.</description>
        <time_frame>Midpoint Chemotherapy, up to 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients Analyzed</title>
            <description>All patients</description>
          </group>
        </group_list>
        <measure>
          <title>Relationships Among Quality of Life Scores - Correlations at Midpoint Chemotherapy</title>
          <description>Simple correlations will be computed at Midpoint Chemotherapy for quality of life scores.</description>
          <units>correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean and Standard Deviation of Biomarkers Log(CRP pg/ml), Log(IL-1b pg/ml), Log(IL-6 pg/ml) and Log(TNF-a pg/ml).</title>
        <description>Simple correlations will be computed after completion of study treatment for the log transformed biomarker values; IL1-β, IL-6, TNF-α, CRP. These are the biomarkers of inflammation.</description>
        <time_frame>Up to 2 weeks after completion of study treatment, for up to 8 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Cranial Microcurrent Electrical Stimulation (CES)</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Sham CES</description>
          </group>
        </group_list>
        <measure>
          <title>Mean and Standard Deviation of Biomarkers Log(CRP pg/ml), Log(IL-1b pg/ml), Log(IL-6 pg/ml) and Log(TNF-a pg/ml).</title>
          <description>Simple correlations will be computed after completion of study treatment for the log transformed biomarker values; IL1-β, IL-6, TNF-α, CRP. These are the biomarkers of inflammation.</description>
          <units>Log (pg/ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Log (CRP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.64" spread="1.26"/>
                    <measurement group_id="O2" value="29.00" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Log (IL-1B)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.50" spread="83.81"/>
                    <measurement group_id="O2" value="1.35" spread="5.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Log (IL6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="2.29"/>
                    <measurement group_id="O2" value="0.73" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Log (TNF-a)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="3.64"/>
                    <measurement group_id="O2" value="-0.33" spread="3.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationships Among Biomarkers Log (CRP), Log (IL-1B), Log (IL6), and Log (TNF-a) - Correlations at End of Treatment</title>
        <description>Simple correlations will be computed at Chemotherapy End of Treatment for the log transformed biomarker values; IL1-β, IL-6, TNF-α, CRP. These are the biomarkers of inflammation.</description>
        <time_frame>Up to 2 weeks afer completion of study treatment, for up to 8 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients Analyzed</title>
            <description>All patients</description>
          </group>
        </group_list>
        <measure>
          <title>Relationships Among Biomarkers Log (CRP), Log (IL-1B), Log (IL6), and Log (TNF-a) - Correlations at End of Treatment</title>
          <description>Simple correlations will be computed at Chemotherapy End of Treatment for the log transformed biomarker values; IL1-β, IL-6, TNF-α, CRP. These are the biomarkers of inflammation.</description>
          <units>correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Correlation between Log (CRP)-Log (IL-1B)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Log (CRP)-Log IL6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Log (CRP)-Log (TNF-a)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Log (IL-1B)-Log (IL6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Log (IL-1B)-Log (TNF-a)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Log (IL6)-Log (TNF-a)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationships Among Anxiety, Depression, Fatigue, Pain and Sleep Scores - Means at End of Chemotherapy</title>
        <description>Measured using Hospital Anxiety and Depression Scale (HADS) a fourteen item scale, 7 relate to anxiety and 7 to depression; each item is scored from 0-3, this means a person can score 0 to 21 for either anxiety or depression (0 is best and 21 is worst), Brief Pain Inventory (BPI) short-form measures the intensity of pain and interference of pain in the patient's life; 12 questions with 0 (does not interfere) to 10 (completely interferes); mean will be used as the measure of pain; Brief Fatigue Inventory (BFI) assess the severity and impact of cancer-related fatigue. it has 9 questions with 0 (does not interfere) to 10 (completely interferes); severe fatigue can be defined as a score of 7 or higher, General Sleep Disturbance Scale (GSDS) 21 items to evaluate sleep issues (0=never to 7=every day); the 21 items are summed to produce a total score of 9=no sleep disturbance to 137=extreme sleep disturbance . Used standard questionnaire scoring system.</description>
        <time_frame>Up to 2 weeks afer completion of study treatment, for up to 8 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Cranial Microcurrent Electrical Stimulation (CES)</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Sham CES</description>
          </group>
        </group_list>
        <measure>
          <title>Relationships Among Anxiety, Depression, Fatigue, Pain and Sleep Scores - Means at End of Chemotherapy</title>
          <description>Measured using Hospital Anxiety and Depression Scale (HADS) a fourteen item scale, 7 relate to anxiety and 7 to depression; each item is scored from 0-3, this means a person can score 0 to 21 for either anxiety or depression (0 is best and 21 is worst), Brief Pain Inventory (BPI) short-form measures the intensity of pain and interference of pain in the patient's life; 12 questions with 0 (does not interfere) to 10 (completely interferes); mean will be used as the measure of pain; Brief Fatigue Inventory (BFI) assess the severity and impact of cancer-related fatigue. it has 9 questions with 0 (does not interfere) to 10 (completely interferes); severe fatigue can be defined as a score of 7 or higher, General Sleep Disturbance Scale (GSDS) 21 items to evaluate sleep issues (0=never to 7=every day); the 21 items are summed to produce a total score of 9=no sleep disturbance to 137=extreme sleep disturbance . Used standard questionnaire scoring system.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.07" spread="3.51"/>
                    <measurement group_id="O2" value="4.51" spread="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.47" spread="3.36"/>
                    <measurement group_id="O2" value="4.63" spread="3.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.34" spread="2.47"/>
                    <measurement group_id="O2" value="3.32" spread="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" spread="1.65"/>
                    <measurement group_id="O2" value="1.32" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.50" spread="20.19"/>
                    <measurement group_id="O2" value="40.91" spread="21.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationships Among Symptom Scores - Correlations at End of Chemotherapy</title>
        <description>Simple correlations will be computed at end of Chemotherapy for symptoms.</description>
        <time_frame>Up to 2 weeks afer completion of study treatment, for up to 8 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients Analyzed</title>
            <description>All patients</description>
          </group>
        </group_list>
        <measure>
          <title>Relationships Among Symptom Scores - Correlations at End of Chemotherapy</title>
          <description>Simple correlations will be computed at end of Chemotherapy for symptoms.</description>
          <units>correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Correlation between Anxiety-Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Anxiety-Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Anxiety-Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Anxiety-Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Depression-Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Depression-Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Depression-Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Fatigue-Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Fatigue-Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correlation between Pain-Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects of Treatment on Quality of Life - Means at End of Treatment</title>
        <description>Measured using the Functional Assessment of Cancer Therapy for Patients with Breast Cancer (FACT-B). A 44-item self-report instrument designed to measure multidimensional quality of life in patient with breast cancer. 0=not at all to 4=very much. Utilized standard questionnaire scoring system. The items are summed to produce a total score 0=not al all to 176=very much. The FACT-B BCA has 10 questions that range from 0 (not at all) to 4 (very much); thus the FACT-B BCA ranges from 0 to 40. Both the FACT-B and FACT-BCA are scored so that high scores indicate higher levels of quality of life.</description>
        <time_frame>up to 2 weeks after completion of study treatment, for up to 8 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Cranial Microcurrent Electrical Stimulation [CES])</title>
            <description>Patients receive a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of biphasic electrical stimulation via ear-lobe electrodes. The CES unit is preset to provide 1 hour of 100 μA (sub-sensory level), modified square-wave biphasic stimulation on a 50% duty cycle at .05 Hz, and to automatically turn off at the end of 1 hour. Patients use their CES unit once daily in weeks 1-18.
energy-based therapy: Given once a day for 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Sham CES)</title>
            <description>Patients receive a CES unit as in arm I, but the ear-lobe electrodes do not pass electrical current. Patients use their CES unit once daily in weeks 1-18.
sham intervention: Given once a day for 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of Treatment on Quality of Life - Means at End of Treatment</title>
          <description>Measured using the Functional Assessment of Cancer Therapy for Patients with Breast Cancer (FACT-B). A 44-item self-report instrument designed to measure multidimensional quality of life in patient with breast cancer. 0=not at all to 4=very much. Utilized standard questionnaire scoring system. The items are summed to produce a total score 0=not al all to 176=very much. The FACT-B BCA has 10 questions that range from 0 (not at all) to 4 (very much); thus the FACT-B BCA ranges from 0 to 40. Both the FACT-B and FACT-BCA are scored so that high scores indicate higher levels of quality of life.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.11" spread="2.52"/>
                    <measurement group_id="O2" value="105.96" spread="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast Cancer Specific</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.51" spread="0.75"/>
                    <measurement group_id="O2" value="24.66" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationships Among Quality of Life Scores - Correlations at End of Chemotherapy</title>
        <description>Simple correlations will be computed at End of Chemotherapy for quality of life scores.</description>
        <time_frame>Up to 2 weeks afer completion of study treatment, for up to 8 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients Analyzed</title>
            <description>All patients</description>
          </group>
        </group_list>
        <measure>
          <title>Relationships Among Quality of Life Scores - Correlations at End of Chemotherapy</title>
          <description>Simple correlations will be computed at End of Chemotherapy for quality of life scores.</description>
          <units>correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 20 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Cranial Microcurrent Electrical Stimulation [CES])</title>
          <description>Patients receive a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of biphasic electrical stimulation via ear-lobe electrodes. The CES unit is preset to provide 1 hour of 100 μA (sub-sensory level), modified square-wave biphasic stimulation on a 50% duty cycle at .05 Hz, and to automatically turn off at the end of 1 hour. Patients use their CES unit once daily in weeks 1-18.
energy-based therapy: Given once a day for 18 weeks</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Sham CES)</title>
          <description>Patients receive a CES unit as in arm I, but the ear-lobe electrodes do not pass electrical current. Patients use their CES unit once daily in weeks 1-18.
sham intervention: Given once a day for 18 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI CTCAE v3.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <description>nonstudy related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Debra Lyon, RN, PhD, FNP</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>804-828-7743</phone>
      <email>delyon@vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

